Pfizer in-licenses Noxxon's NOX-B11

Noxxon (Berlin, Germany) granted PFE an exclusive worldwide license to develop and commercialize NOX-B11, a preclinical ghrelin receptor antagonist, to treat obesity. The compound, which was developed...